Novo Nordisk buys Ginkgo Bioworks’ autonomous lab. Can robotics rescue its shrinking revenue?
Ginkgo Bioworks sells its first pharma autonomous lab to Novo Nordisk as Q3 losses narrow. Examine revenue, cash burn and execution.
Medical Devices & Diagnostics
Pharma & Biotech
Genmab’s Rina-S slashed progression risk by 71%, but can it challenge ovarian cancer treatment standards?
Genmab's Rina-S cut progression risk by 71% and showed an overall survival benefit in Phase 3 ovarian cancer data. What remains before approval?
Pharma & Biotech
Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials
Roivant's brepocitinib succeeds in two Phase 3 uveitis trials, improving steroid-free disease control. Explore the results and FDA plans.
Pharma & Biotech
AbbVie Skyrizi achieves 35.8% endoscopic remission in Phase 3 Crohn’s disease study
New Phase 3 AFFIRM data show 35.8% endoscopic remission and 36.6% ulcer-free endoscopy with subcutaneous Skyrizi at Week 24. The findings support regulatory applications for an alternative to intravenous induction, although differences in treatment allocation after Week 12 require careful interpretation.
Pharma & Biotech
Skyrizi reaches 73.1% remission in a Crohn’s subgroup. Can AbbVie secure a new FDA dosing option?
AbbVie reports new Skyrizi and Rinvoq Crohn's disease data, including Phase III remission results and long-term findings. Examine the evidence.
Features & Analysis
Solengepras cut Parkinson’s OFF time by 37 minutes. Is a non-dopamine mechanism enough to matter?
Cerevance’s solengepras has met the primary endpoint in the Phase 3 ARISE trial, reducing daily Parkinson’s OFF time by 0.61 hours versus placebo while also improving ON time and daily motor function. The result validates a novel GPR6-based, non-dopaminergic approach, but the absolute effect was smaller than in Phase 2 and arrives just as AbbVie
Pharma & Biotech
AbbVie’s $2.5bn Rinvoq franchise reaches children as young as two after EU approval
The European Commission has approved Rinvoq for active polyarticular juvenile idiopathic arthritis in children aged two and older, adding another patient population to AbbVie’s rapidly growing immunology franchise and introducing a weight-based oral solution for younger patients.
Pharma & Biotech
AbbVie’s etentamig cuts myeloma progression risk 60% as monthly bispecific strategy nears its real test
AbbVie will present full Phase 3 CERVINO data for etentamig after the BCMA bispecific produced a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.
Features & Analysis
AbbVie’s second-generation BCMA bispecific succeeded in Phase 3. What makes CERVINO commercially important?
AbbVie’s etentamig delivered a 74% response rate and reduced the risk of progression or death by 60% in the Phase 3 CERVINO trial. Its real competitive proposition, however, may be operational: monthly dosing after a single step-up dose could help move BCMA-directed T-cell therapy beyond specialist centres.
Pharma & Biotech
AbbVie’s new multiple myeloma bispecific posts 74% response rate versus 45.7% with standard therapy
AbbVie’s Phase 3 CERVINO trial met both primary endpoints as etentamig achieved a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.